Summary

Eligibility
for people ages 40 years and up (full criteria)
Location
at UCSF
Dates
study started
study ends around
Principal Investigator
by Tom Martin, MD (ucsf)

Description

Summary

In this multicenter study, we will recruit 400 patients 40 years of age or older at 15 centers with a diagnosis of smoldering multiple myeloma (SMM), a group of patients for whom standard of care is observation not treatment. The main goal of this study is to screen for the diagnosis of light-chain amyloidosis (AL) before the onset of symptomatic disease and to develop a training set for a likelihood algorithm.

Details

This study is based on results from two prior studies in which 4 of 36 patients with SMM and none of 14 patients with MGUS were found to have AL. The hypothesis that we test with this protocol is that patients with (1) a pre-existing diagnosis of SMM, (2) free light chain (FLC) abnormalities, (3) IGLV genes associated with AL,(4) t(11;14) or gain 1q, and (5) NT-proBNP > 332pg/mL will have undiagnosed AL or risk of progression to AL. We will study the potential for SMM, the FLC screen, AL-related IGLV gene use, t(11;14) or gain 1q cytogenetic abnormalities, and NT-proBNP > 332pg/mL to be the variables in a likelihood algorithm for AL.

Keywords

Smoldering Multiple Myeloma, SMM, AL Amyloidosis, Immunoglobulin Light-chain Amyloidosis

Eligibility

You can join if…

Open to people ages 40 years and up

  • Patients 40 years of age and older
  • diagnosed with either Smoldering Multiple Myeloma or a Monoclonal Gammopathy
  • dFLC greater than 23 mg/L
  • abnormal FLC ratio
  • If the patient has an eGFR less than 50 mL/min/1.73m2, the FLC ratio is inconsequential. The patient only needs to meet the age and dFLC criterion.

You CAN'T join if...

  • Patients younger than 40 years of age are not eligible
  • Patients with a previous finding of amyloid in other biopsies will not be included
  • Adults unable to consent are not eligible, including the cognitively impaired Pregnant women, pregnant minors, minors (i.e., individuals who are not yet adults), wards of the state, non-viable neonates, neonates of uncertain viability, and prisoners are not eligible

Locations

  • University of California, San Francisco accepting new patients
    San Francisco 5391959 California 5332921 94143 United States
  • Cedars-Sinai Medical Center accepting new patients
    Los Angeles 5368361 California 5332921 90048 United States

Lead Scientist at University of California Health

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Tufts Medical Center
ID
NCT06365060
Study Type
Observational
Participants
Expecting 400 study participants
Last Updated